Sacituzumab tirumotecan for lung cancer (TroFuse-004)

Sac-TMT (TROP2 ADC) showed encouraging Ph2 OptiTROP-Lung03 data in EGFR-mutated NSCLC post-TKI/chemo vs docetaxel, with ORR and PFS benefit. OS endpoint in this heavily pretreated population is achievable given docetaxel's weak comparator (~8-10mo OS). Merck's execution is strong. However, OS crossover risk and prior ADC Ph3 OS failures (e.g., Dato-DXd TROPION-Lung01) temper confidence. PFS likely positive; OS modestly favored.

Randomized Phase 3 design, completed enrollment, and a hard OS endpoint support rigor. However, OS superiority in previously treated EGFR-mutant NSCLC is demanding, chemotherapy choice adds variability, follow-up is long, and no sample size or prior efficacy evidence is provided.

This is a randomized Phase 3 study in previously treated, molecularly selected NSCLC with OS as a rigorous, clinically meaningful endpoint. Completion is near and enrollment is finished, reducing execution risk, but demonstrating OS superiority over active chemotherapy in a heterogeneous, heavily pretreated driver-altered population remains a high bar.

Phase 3 and Active Not Recruiting suggest a mature, operationally credible study, while OS is a clinically meaningful hard endpoint. However, this is previously treated, biomarker-diverse NSCLC with substantial treatment heterogeneity and a demanding superiority comparison against chemotherapy. The provided facts offer no prior efficacy or interim signal, so a positive OS result is plausible but below even odds.

Phase 3 superiority OS trial vs chemo in post-EGFR TKI NSCLC (EGFR-mut or select alterations). Hard OS endpoint with long follow-up (~41 mo) and risks from subsequent therapies/crossover. Active not recruiting but 237 days to primary completion; no sample size, HR target, or prior OS data disclosed. Typical oncology Ph3 success rate tempered by endpoint difficulty.

Sacituzumab tirumotecan (MK-2870) has highly de-risked efficacy in EGFRm NSCLC. The Phase 3 OptiTROP-Lung04 trial in China demonstrated a statistically significant OS benefit vs chemotherapy in this exact setting, as did the OptiTROP-Lung03 study (OS HR 0.63 vs docetaxel). While TROP2 ADCs have failed OS in unselected NSCLC, MK-2870 is exceptionally active in EGFR-mutant disease. TroFuse-004 has a high probability of replication.

Phase‑3 trial tests an ADC versus standard chemo in previously‑treated EGFR‑mutated NSCLC. Limited prior efficacy data, challenging OS endpoint, and strong historical control performance suggest modest benefit. The breadth of genomic sub‑populations adds heterogeneity, lowering confidence in a clear survival advantage.

Phase 3 MK-1084 (Trop-2 ADC) vs chemo in EGFR-mutated NSCLC post-TKI. ADC class precedent is mixed: Trodelvy EVOKE-01 failed OS in all-comer 2L NSCLC, tempering optimism. However, EGFR-mutated subgroup has high unmet need with pemetrexed/docetaxel as a weak comparator, lowering the bar. Active not recruiting signals enrollment completion. OS is a rigorous endpoint harder to game. No published Phase 2 OS data in EGFR subgroup to anchor a stronger prior. Roughly coin-flip.